Preop prostate MRI findings predict cancer recurrence at rates similar to pathology, analysis shows

Preoperative prostate MRI exams can offer added value in predicting biochemical recurrence (BCR) of prostate cancer and often perform comparably to post-surgical pathologic staging. 

That’s according to new data published in the American Journal of Roentgenology, comparing the utility of pre-surgical staging information from MRI and post-surgical staging information from radical prostatectomy (RP) pathology in predicting cancer recurrence. A group of experts involved in the study looked at the cases of 604 patients with prostate cancer who underwent both preoperative MRI and postoperative pathology and found that the BCR-free survival rates were comparable using each staging method—a finding that could improve preoperative assessments for prostate cancer patients, the group suggested. 

“MRI staging can preoperatively identify patients at high BCR risk, helping to inform early clinical decision making,” corresponding author Baris Turkbey, MD, with the Molecular Imaging Branch of the National Cancer Institute in Bethesda, Maryland, and colleagues noted.

For their study, the group had a genitourinary radiologist retrospectively analyze the cases of patients who underwent prostate MRI before RP from June 2007 to December 2018. Exams were assessed specifically for extraprostatic extension (EPE) and seminal vesicle invasion (SVI); those findings were then compared to outcomes to better understand how they might relate to BCR. 

When compared to the patient’s postoperative pathology results, the presence and/or absence of both EPE and SVI on imaging provided similar value in predicting cancer recurrence, ranging by just a few percentage points in multiple metrics. 

Currently, BCR prediction is based largely on results from postoperative RP specimens but given the similarities in accuracy between pathology results and preoperative imaging, MRI could have a greater role in risk assessments in the future, the group suggested. 

The study abstract is available here

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Elucid's PlaqueIQ was trained to turn CCTA images into interactive 3D reports that help physicians visualize the presence of atherosclerosis.

Trimed Popup
Trimed Popup